Objectives-To estimate the complement activating properties of monoclonal, monoreactive, and polyreactive IgM rheumatoid factors derived from Epstein-Barr virus transformed B
Human C4 was purified as described previously.'2 13 Based on the results from sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) as described by Laemmli, 14 it was homologous under nonreducing conditions and showed the appropriate molecular weight for its polypeptide chains under reducing conditions. Antiserum to C4 was prepared by immunising a rabbit with the purified C4. The rabbit antiserum to human C4 was purified using a Sepharose 4B (Pharmacia, Uppsala, Sweden) column coupled with the human C4. The purified rabbit antibody to human C4 was then applied to Sephacryl S-300 (Pharmacia, Uppsala, Sweden) in PBS, and the IgG fractions were collected. The rabbit IgG antibody to human C4 was dialysed against 0-1 M acetate buffer (pH 4 4) and subjected to pepsin digestion. IgG (36 mg) in 10 ml of solution was mixed with 0-72 mg pepsin and incubated for 18 hours at 37°C. The digestion was stopped by adjusting the pH to 7-4 with 1-0 M Tris-HC1 (pH 9 0) and the material was dialysed against PBS. The F(ab')2 fragment of the IgG antibody to human C4 was separated from Fc and undigested IgG by a Protein A-Sepharose 4B column (Pharmacia, Piscataway, NJ, USA). The purity of the F(ab')2 fragment of the antibody to human C4 was assessed by SDS-PAGE. No contamination with intact IgG or Fc fragments was observed. Biotinylation of rabbit F(ab')2 antibody to human C4 was performed by the same method as described previously. 5 The capability of this biotinylated F(ab')2 antibody for detecting human C4 was assessed by immunoblotting. Normal human serum, diluted to 1:100 with PBS, was subjected to SDS-PAGE under non-reducing conditions and then transblotted onto a nitrocellulose membrane. The membrane was blocked with 5% BSA in PBS for one hour at 37°C, and incubated for one hour with 1 ,ug/ml biotinylated F(ab')2 antibody to human C4, which had been diluted with PBS-Tween containing 1% BSA. After washing the membrane was treated with the Vectastatin ABC-AP kit (Vector Laboratories, Sunnyvale, CA, USA) according to the manufacturer's instructions. The membrane was then developed using 5-bromo-4-chloro-3-indolylphosphatase toluidine salt/ p-nitroblue tetrazolium chloride as a substrate. For inhibition experiments, the F(ab')2 antibody to human C4 (1 ,ug/ml) was incubated with the purified human C4 (1 mg/ml) for two hours at room temperature before testing by immunoblotting. Mg2+ (GVB2+), was added to the wells and incubated for one hour at 37°C. Normal human serum heated at 56°C for 30 minutes was also used as an inactivated complement. A 100 RI volume of 1 ,ug/ml biotinylated rabbit F(ab')2 antibody to human C4 diluted in PBSTween was then added and incubated for one hour at 37°C. The wells then received avidinbiotin-alkaline phosphatase complex (ABC) (Vector Laboratories), which had been mixed in PBS-Tween 30 minutes before use. The wells were then incubated for one hour at 37°C. The p-nitrophenylphosphate substrate (Sigma) was then added to the wells and the colour appearing was read under a spectrophotometer with absorbance at 405 nm; the amounts of bound C4 were expressed as absorbance values. The complement activating property of IgM rheumatoid factor bound to IgG Fc was tentatively expressed as a ratio of the amount of bound C4 (absorbance value) to the amount of bound 1gM (absorbance value). All experiments were performed in duplicate.
To determine the optimum concentration of each monclonal IgM rheumatoid factor solution for the ELISA, preliminary experiments were performed using various concentrations (data not shown). The different solutions showed similar levels of IgM rheumatoid factor binding; the results all fell within the C4 binding curve representing values obtained from serial dilution of each IgM rheumatoid factor. The IgM concentration in each IgM rheumatoid factor solution was determined by ELISA using the same method for IgM rheumatoid factor as described earlier, except for coating of each plate with unconjugated goat F(ab')2 antibody to human IgM (Tago), diluted to 1:1000 with carbonate-hydrogencarbonate buffer, pH 9-6. The dose dependent binding curve for IgM at a known concentration was used as a standard curve. As a result of this procedure, we found that the optimum concentrations of monoreactive IgM rheumatoid factors ranged from 0 3 to 1 pug/ml, and those polyreactive IgM rheumatoid factors ranged from 1 to 2 ,ug/ml. At these optimum concentrations, the amounts of bound IgM rheumatoid factors were such that non-specific binding of IgM from normal human serum was negligible. In this study, among eight monoclonal IgM rheumatoid factor producing cell clones obtained from the peripheral blood of two patients with RA, only two clones were found to produce monoreactive IgM rheumatoid factor. In contrast, four monoclonal IgM rheumatoid factor producing cell clones derived from one synovial tissue sample all produced monoreactive IgM rheumatoid factor. Although the number of clones obtained was too small to reach a definite conclusion, our results suggest that the proportion of monoreactive rheumatoid factor producing B cell precursors is higher in synovial tissue than in peripheral blood in RA. Our finding is in agreement with the studies reported by Randen et al, which showed that 14 monoclonal rheumatoid factors were monoreactive among 20 monoclonal rheumatoid factor producing clones isolated from the synovial fluid of two patients with RA and one patient with juvenile RA. 16 Burastero et al also showed that most cell lines derived from rheumatoid synovial fluid produced monoreactive rheumatoid factor.
The observed higher affinity of monoreactive IgM rheumatoid factor to IgG Fc, shown by Kd values two orders of magnitude larger than those of polyreactive IgM rheumatoid factors, coincides with the findings published by other workers.2 3 Harindranath et al,5 by sequencing the genes of the two types of monoclonal rheumatoid factors in one patient with RA, showed that the VH genes of low affinity polyreactive rheumatoid factors were in germline configuration. In contrast, the VH genes of monoreactive high affinity rheumatoid factor showed somatic point mutation, possibly as the result of a process of clonal selection driven by antigens. Along these lines, it is possible that an antigen driven process of clonal selection and somatic mutation could lead to the generation of monoreactive high affinity rheumatoid factor as the maturation of immune response to an antigen is often characterised by an increase in antibody affinity and a decrease in the heterogeneity of antibody specificity.17 18 The precise mechanism by which monoreactive IgM rheumatoid factor shows higher complement activating properties is unclear. Feinstein 
